Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Villano, Bert C. Del; Brennan, Seamus P.; Brock, Pénélope; Bucher, Christoph; Liu, V; McClure, Myra O.; Rake, Beaven; Space, Sharon; Westrick, Barbara; Schoemaker, H.J.; Zurawski, Vincent R.

doi:10.1093/clinchem/29.3.549

Cited by 438 publications

(77 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We ascertained in our prospective study a sensitivity of 92% for this monoganglioside antigen for pancreatic carcinoma, a specificity of 85%, and a total accuracy of 82%. In accordance with the existing findings and the results of Del Villano et al" and Klapdor et al,[1][2][3][4][5][6][7][8][9][10][11][12] who confirmed this high sensitivity, measurement of CA 19-9 value is superior to all other tumor markers in pancreatic carcinoma patients.…”

Section: Discussionsupporting

confidence: 89%

CA 19-9 and pancreatic adenocarcinoma

Safi

Beger

Bittner

et al. 1986

Cancer

View full text Add to dashboard Cite

The diagnostic place value of CA 19-9, a tumor-associated antigen, was tested in 611 patients. This group of patients included 273 patients who suffered from a malignant disease (48 patients with pancreatic carcinomas and 225 patients with extrapancreatic malignant growths) and 338 patients with benign diseases (66 patients with chronic pancreatitis, 36 patients with acute pancreatitis, and 236 patients with general surgical diseases). In 93% of the patients with pancreatic carcinoma (media value, 528 U/ml), in 37% and 19% of the patients with carcinoma of the stomach and colorectal carcinomas (median value 8 U/ml), respectively, the CA 19-9 value was estimated as being above the normal limits of 6 to 37 U/ml. A sensitivity of 93% and a specificity of 85%, as well as a total accuracy of 82%, were established in pancreatic carcinoma during preoperative observation. The preoperatively raised CA 19-9 concentration in patients with pancreatic carcinomas dropped after curative resection of the carcinoma to within normal limits. However, a serum concentration of less than 37 U/ml was not recorded in any CA 19-9 estimation after a palliative surgical intervention, or in any case of inoperable carcinomas.

show abstract

Section: Discussionsupporting

confidence: 89%

CA 19-9 and pancreatic adenocarcinoma

Safi

Beger

Bittner

et al. 1986

Cancer

View full text Add to dashboard Cite

show abstract

“…carcinomas and in approximately 70% of breast carcinomas Serum radioimmunoassays for the detection of tumor associated antigens (TAAs) have been used to monitor the course of disease of several carcinomas ( 1-7). The more widely used assays are: carcinoembryonic antigen (CEA) for colorectal cancer (1,2), CA 15-3 for breast cancer (5,6), CA 125 (measuring OC-125) for ovarian cancer (3), CA 19-9 (measuring GICA) for colorectal and pancreatic cancer (4), and DuPAN-2 for pancreatic cancer (7). While each of these assays has its advantages and disadvantages, none is comprehensive in predicting or determining the disease status in all patients of a given tumor type.…”

Section: Introductionmentioning

confidence: 99%

Ca 72‐4 radioimmunoassay for the detection of the tag‐72 carcinoma‐associated antigen in serum of patients

Gerö¹,

Colcher

Ferroni³

et al. 1989

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Monoclonal antibody (MAb)B72.3 has been used to detect the presence of TAG-72 in the serum of carcinoma patients. We have developed new anti-TAG-72 MAbs and have selected one of these, CC49, as the "catcher" MAb with 125I-B72.3 as the detecting antibody in a double-determinant immunoradiometric assay. This combination enabled the development of a sequential assay (designated CA 72-4) that showed optimal quantitative properties as demonstrated by such parameters as linear dose-response, high re-producibility, and lack of serum-matrix and "hook-back" effects. Only 3.5% of 744 normal sera and 6.7% of 134 sera from patients with benign gastrointestinal diseases had TAG-72 levels greater than 6 U/ml. Approximately 40% of 303 patients with gastrointestinal malignancies had serum TAG-72 levels of greater than 6 U/ml (55% of the patients with advanced disease). Thirty-six percent of patients with adenocarcinomas of the lung and 24% of patients with ovarian cancer (53% stage IV patients) also had elevated serum TAG-72 levels. A poor correlation was found between the carcinoembryonic antigen (CEA) and TAG-72 values of sera obtained from gastric cancer patients. Thirty-four percent of CEA negative cases were scored positive in the CA 72-4 assay, suggesting the complementarity of the CA 72-4 assay to CEA assays in the analysis of sera from patients with certain malignancies.

show abstract

“…The sLe a determinant is known to be secreted from cancer cells into the general circulation, and is sometimes utilized as a serum tumor marker under the name of CA 19-9 [9,17,18], the level of sLe a in serum is dependent on the Lewis blood subtype of patients [19]. Significantly, this sLe a level is elevated in a variety of carcinomas, particularly those of the pancreas, stomach, and colon, and the association of high levels of serum sLe a with tumor invasion is common in cancer patients [20][21][22][23]. The detection of sLe a in pre-and postoperative serum is thus a predictor of increased cancer mortality [24].…”

Section: Introductionmentioning

confidence: 99%

Glycomic mapping of pseudomucinous human ovarian cyst glycoproteins: Identification of Lewis and sialyl Lewis glycotopes

Wu¹,

Khoo²,

Yu³

et al. 2007

Proteomics

View full text Add to dashboard Cite

Expression of sialyl Lewis x (sLe(x)) and sialyl Lewis a (sLe(a)) on cell-surface glycoproteins endows cells with the ability to adhere to E-, P-, and L-selectins present on endothelia, platelets, or leukocytes. Special arrangements of these glycotopes in cancers are thought to play a key role in metastasis. Previous studies have mostly described membrane-bound sLe(x) and sLe(a) activities. In this report, the major O-glycans of the secreted human ovarian cyst sialoglycoproteins from a Le(a+) nonsecretor individual (human ovarian cyst sample 350) were characterized by MS/MS analyses and immuno-/lectin-chemical assays. The results showed that HOC 350 carries a large number of epitopes for sLe(x), sLe(a), and Le(a) reactive antibodies. Advanced MS/MS sequencing coupled with mild periodate oxidation and exoglycosidase digestions further revealed that the O-glycans from HOC 350 are mostly of core 1 and 2 structures, extended and branched on the 3-arm with both type I and type II chains, complete with variable degrees of terminal sialylation and/or fucosylation to yield the sLe(x) or sLe(a) epitopes. Thus, the underlying core and peripheral backbone structures are similar to that of a previously proposed composite structural model for nonsialylated human ovarian cysts O-glycans, but with some notable distinguishing structural features in addition to sialylation.

show abstract

Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Cited by 438 publications

References 0 publications

CA 19-9 and pancreatic adenocarcinoma

CA 19-9 and pancreatic adenocarcinoma

Ca 72‐4 radioimmunoassay for the detection of the tag‐72 carcinoma‐associated antigen in serum of patients

Glycomic mapping of pseudomucinous human ovarian cyst glycoproteins: Identification of Lewis and sialyl Lewis glycotopes

Contact Info

Product

Resources

About